NY-ESO-1 antibody as a novel tumour marker of gastric cancer

British Journal of Cancer

Volumn 108, Issue 5, 2013, Pages 1119-1125

  Fujiwara, S ^a   Wada, H ^a   Kawada, J ^a   Kawabata, R ^a   Takahashi, T ^a   Fujita, J ^b   Hirao, T ^c   Shibata, K ^c   Makari, Y ^d   Iijima, S ^d   Nishikawa, H ^a   Jungbluth, A A ^e   Nakamura, Y ^a   Kurokawa, Y ^a   Yamasaki, M ^a   Miyata, H ^a   Nakajima, K ^a   Takiguchi, S ^a   Nakayama, E ^f   Mori, M ^a   Doki, Y ^a   more..

^a OSAKA UNIVERSITY   (Japan)

^b TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^c Ikeda City Hospital   (Japan)

^d Minoh City Hospital   (Japan)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f KAWASAKI UNIVERSITY OF MEDICAL WELFARE   (Japan)

Author keywords

detection marker; follow up marker; prognosis; recurrence; surgical treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CANCER ANTIBODY; CARCINOEMBRYONIC ANTIGEN; NY ESO 1 ANTIGEN;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER;

AGED; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CARCINOEMBRYONIC ANTIGEN; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNITY, HUMORAL; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84875469309     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.51     Document Type: Article

References (34)

1. Alexander JC, Silverman NA, Chretien PB (1976) Effect of ageand cigarette smoking on carcinoembryonic antigen levels. JAMA 235:1975-1979.
2. Austrup F, Uciechowski P, Eder C, Böckmann B, Suchy B, Driesel G, Jäckel S, Kusiak I, Grill HJ, Giesing M (2000) Prognostic value of genomicalterations in minimal residual cancer cells purified from the blood ofbreast cancer patients. Br J Cancer 83: 1664-1673.
3. Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J (2007) Autoantibodies in breast cancer: their use asan aid to early diagnosis. Ann Oncol 18: 868-873.
4. Ferro MA, Barnes I, Roberts JB, Smith PJ (1987) Tumor markers in prostaticcarcinoma. A comparison of prostate-specific antigen with acidphosphatase. Br J Urol 60: 69-73.
5. Fujiyama S, Morishita T, Sagara K, Sato T, Motohara K, Matsuda I (1986) Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) inpatients with hepatocellular carcinoma. Hepatogastroenterology 33: 201-205.
6. Gati A, Lajmi N, Derouiche A, Marrakchi R, Chebil M, Benammar-Elgaaied A (2011) NY-ESO-1 expression and immunogenicity in prostate cancerpatients. Tunis Med 89: 779-783.
7. Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, Knuth A, Chen YT, Old LJ (2006) NY-ESO-1: review of an immunogenic tumorantigen. Adv Cancer Res 95: 1-30.
8. Graziosi L, Bugiantella W, Cavazzoni E, Cantarella F, Porcari M, Baffa N, Donini A (2011) Role of FDG-PET/CT in follow-up of patients treatedwith resective gastric surgery for tumour. Ann Ital Chir 82: 125-129.
9. Health and Welfare Statistics Association: Tokyo (2006) Statistics andInformation Department, Ministry of Health, Labour, and Welfare VitalStatistics of Japan 2004.
10. Ikeda Y, Mori M, Adachi Y, Matsushima T, Sugimachi K, Saku M (1993) Carcinoembryonic antigen (CEA) in stage IV gastric cancer as a risk factorfor liver metastasis: a univariate and multivariate analysis. J Surg Oncol 53:235-238.
11. Isobe M, Eikawa S, Uenaka A, Nakamura Y, Kanda T, Kohno S, Kuzushima K, Nakayama E (2009) Correlation of high and decreased NY-ESO-1immunity to spontaneous regression and subsequent recurrence in a lungcancer patient. Cancer Immun 9: 8.
12. Jäger E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jäger D, Arand M, Ritter G, Old LJ, Knuth A (1999) Humoral immune responses of cancerpatients against 'Cancer-Testis' antigen NY-ESO-1: correlation withclinical events. Int J Cancer 84: 506-510.
13. Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, Nakajima J, Seto Y, Yamatsuji T, Naomoto Y, Shiraishi K, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Oka M, Pan L, Hoffman EW, Old LJ, Nakayama E (2011) Aphase I study of vaccination with NY-ESO-1f peptide mixed with PicibanilOK-432 and Montanide ISA-51 in patients with cancers expressing theNY-ESO-1 antigen. Int J Cancer 129: 2836-2846.
14. Katanoda K, Yako-Suketomo H (2009) Comparison of time trends in stomachcancer incidence (1973-2002) in Asia, from Cancer Incidence in FiveContinents, Vols IV-IX. Jpn J Clin Oncol 39: 71-72.
15. Kawada J, Wada H, Isobe M, Gnjatic S, Nishikawa H, Jungbluth AA, OkazakiN, Uenaka A, Nakamura Y, Fujiwara S, Mizuno N, Saika T, Ritter E, Yamasaki M, Miyata H, Ritter G, Murphy R, Venhaus R, Pan L, Old LJ, Doki Y, Nakayama E (2012) Heteroclitic serological response inesophageal and prostate cancer patients after NY-ESO-1 proteinvaccination. Int J Cancer 130: 584-592.
16. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, Riethmüller G (2002) Genetic heterogeneity of singledisseminated tumour cells in minimal residual cancer. Lancet 360:683-689.
17. Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T, Kito T (1996) The prognostic value of preoperative serum levels ofCEA and CA19-9 in patients with gastric cancer. Am J Gastroenterol 91:49-53.
18. Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP (1995) P53antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res 1: 1463-1469.
19. Makino T, Fujiwara Y, Takiguchi S, Miyata H, Yamasaki M, Nakajima K, Nishida T, Mori M, Doki Y (2010) The utility of pre-operative peritoneallavage examination in serosa-invading gastric cancer patients. Surgery 148:96-102.
20. Motoori M, Takemasa I, Doki Y, Saito S, Miyata H, Takiguchi S, Fujiwara Y, Yasuda T, Yano M, Kurokawa Y, Komori T, Yamasaki M, Ueno N, Oba S, Ishii S, Monden M, Kato K (2006) Prediction of peritoneal metastasis inadvanced gastric cancer by gene expression profiling of the primary site.Eur J Cancer 42: 1897-1903.
21. Müller M, Meyer M, Schilling T, Ulsperger E, Lehnert T, Zentgraf H, Stremmel W, Volkmann M, Galle PR (2006) Testing for anti-p53antibodies increases the diagnostic sensitivity of conventional tumormarkers. Int J Oncol 29: 973-980.
22. Nakada T, Noguchi Y, Satoh S, Ono T, Saika T, Kurashige T, Gnjatic S, Ritter G, Chen YT, Stockert E, Nasu Y, Tsushima T, Kumon H, Old LJ, Nakayama E (2003) NY-ESO-1 mRNA expression and immunogenicity inadvanced prostate cancer. Cancer Immunol 3: 10.
23. Pardoll DM (2012) The blockade of immune checkpoints in cancerimmunotherapy. Nat Rev Cancer 12: 252-264.
24. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y (2011) Five-year outcomesof a randomized phase III trial comparing adjuvant chemotherapy withS-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387-4393.
25. Seamonds B, Yang N, Anderson K, Whitaker B, Shaw LM, Bollinger JR (1986) Evaluation of prostate-specific antigen and prostatic acid phosphatase asprostate cancer markers. Urology 28: 472-479.
26. Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, Kobayashi S, Ochiai T (2000) Serum p53 antibody is a useful tumor marker in superficial esophagealsquamous cell carcinoma. Cancer 89: 1677-1683.
27. Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ (1998) A survey of the humoral immune response of cancerpatients to a panel of human tumor antigens. J Exp Med 187: 1349-1354.
28. Takahashi Y, Mai M, Kusama S (1998) Factors influencing growth rate ofrecurrent stomach cancer as determined by analysis of serumcarcinoembryonic antigen. Cancer 75: 1497-1502.
29. Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, Kodaira S, Okajima K, Nakazato H (2003) The usefulness of CEA and/or CA19-9 inmonitoring for recurrence in gastric cancer patients: a prospective clinicalstudy. Gastric Cancer 6: 142-145.
30. Türeci O, Mack U, Luxemburger U, Heinen H, Krummenauer F, Sester M, Sester U, Sybrecht GW, Sahin U (2006) Humoral immune responses of lungcancer patients against tumor antigen NY-ESO-1. Cancer Lett 236: 64-71.
31. Uenaka A, Wada H, Isobe M, Saika T, Tsuji K, Sato E, Sato S, Noguchi Y, Kawabata R, Yasuda T, Doki Y, Kumon H, Iwatsuki K, Shiku H, MondenM, Jungbluth AA, Ritter G, Murphy R, Hoffman E, Old LJ, Nakayama E (2007) T cell immunomonitoring and tumor responses in patientsimmunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun 7: 9.
32. Wada H, Sato E, Uenaka A, Isobe M, Kawabata R, Nakamura Y, Iwae S, Yonezawa K, Yamasaki M, Miyata H, Doki Y, Shiku H, Jungbluth AA, Ritter G, Murphy R, Hoffman EW, Old LJ, Monden M, Nakayama E (2008) Analysis of peripheral and local anti-tumor immune response inesophageal cancer patients after NY-ESO-1 protein vaccination. Int JCancer 123: 2362-2369.
33. Yamamoto M, Baba H, Kakeji Y, Endo K, Ikeda Y, Toh Y, Kohnoe S, Okamura T, Maehara Y (2004) Prognostic significance of tumor markersin peritoneal lavage in advanced gastric cancer. Oncology 67: 19-26.
34. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, HalabanR, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S (2011) Integrated NY-ESO-1 antibody and CD8\+ T-cell responses correlate withclinical benefit in advanced melanoma patients treated with ipilimumab.Proc Natl Acad Sci USA 108: 16723-16728.